Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
It is biology driven and not exactly by lack of discipline
Journal Diabetes Complications
Although all unimolecular triple agonists in phase 2 trials for obesity are GLP1/GIP/GCG triple agonists, there is an ongoing phase 2 clinical trial of bioglutide, an oral insulin-like-growth factor-1 (IGF-1)/GLP-1/GIP/GCG quadruple agonist (NCT06564753) for individuals with obesity, which is also being trialled in combination with tirzepatide (NCT06643728)
It has a relatively short half-life, a strong ability to delay gastric emptying, and an affinity for GLP-1 receptor that is four times that of natural GLP-1
Therapeutic peptides are selected to support specific physiologic pathways, such as promoting growth hormone release for body composition, supporting tissue repair and recovery, improving sleep quality, optimizing metabolism, and encouraging healthy aging
US$ 21.80
US$ 23.63
US$ 29.22
US$ 26.71
US$ 29.96
US$ 27.00
